Development and evaluation of the Nurotron 26-electrode cochlear implant system  by Zeng, Fan-Gang et al.
lable at ScienceDirect
Hearing Research 322 (2015) 188e199Contents lists avaiHearing Research
journal homepage: www.elsevier .com/locate/hearesReviewDevelopment and evaluation of the Nurotron 26-electrode cochlear
implant system
Fan-Gang Zeng a, *, Stephen J. Rebscher b, Qian-Jie Fu c, Hongbin Chen d, Xiaoan Sun d,
Li Yin d, Lichuan Ping d, Haihong Feng e, Shiming Yang f, Shusheng Gong g, Beibei Yang h,
Hou-Yong Kang i, Na Gao j, Fanglu Chi j, **
a Center for Hearing Research, University of California, Irvine, CA 92697, USA
b Department of Otolaryngology e Head and Neck Surgery, University of California, San Francisco, CA 94143, USA
c Department of Otolaryngology e Head and Neck Surgery, University of California, Los Angeles, CA 90095, USA
d Nurotron Biotechnology Inc., Hangzhou, Zhejiang 310011, China
e Shanghai Acoustics Laboratory, Institute of Acoustics, Chinese Academy of Sciences, Shanghai 200032, China
f Department of Otolaryngology e Head and Neck Surgery, Chinese PLA General Hospital, Beijing 100853, China
g Department of Otolaryngology e Head and Neck Surgery, Beijing Tongren Hospital of Capital Medical University, Beijing 100730, China
h Department of Otolaryngology e Head and Neck Surgery, The Second Afﬁliated Hospital of Zhejiang University, Hangzhou 310000, China
i Department of Otolaryngology e Head and Neck Surgery, The First Afﬁliated Hospital of Chongqing Medical University, Chongqing 400016, China
j Department of Otolaryngology e Head and Neck Surgery, The Eye and ENT Hospital of Fudan University, Shanghai 200031, Chinaa r t i c l e i n f o
Article history:
Received 17 June 2014
Received in revised form
18 August 2014
Accepted 3 September 2014
Available online 2 October 2014* Corresponding author. 110 Medical Science E, Univ
92697-5320, USA. Tel.: þ1 949 824 1539; fax: þ1 949
** Corresponding author. 83 Fenyang Road, Xujiahu
China.
E-mail addresses: fzeng@uci.edu (F.-G. Zeng), chifa
http://dx.doi.org/10.1016/j.heares.2014.09.013
0378-5955/© 2014 The Authors. Published by Elseviera b s t r a c t
Although the cochlear implant has been widely acknowledged as the most successful neural prosthesis,
only a fraction of hearing-impaired people who can potentially beneﬁt from a cochlear implant have
actually received one due to its limited awareness, accessibility, and affordability. To help overcome these
limitations, a 26-electrode cochlear implant has been developed to receive China's Food and Drug
Administration (CFDA) approval in 2011 and Conformite Europeenne (CE) Marking in 2012. The present
article describes design philosophy, system speciﬁcation, and technical veriﬁcation of the Nurotron de-
vice, which includes advanced digital signal processing and 4 current sources with multiple amplitude
resolutions that not only are compatible with perceptual capability but also allow interleaved or
simultaneous stimulation. The article also presents 3-year longitudinal evaluation data from 60 human
subjects who have received the Nurotron device. The objective measures show that electrode impedance
decreased within the ﬁrst month of device use, but was stable until a slight increase at the end of two
years. The subjective loudness measures show that electric stimulation threshold was stable while the
maximal comfort level increased over the 3 years. Mandarin sentence recognition increased from the
pre-surgical 0%-correct score to a plateau of about 80% correct with 6-month use of the device. Both
indirect and direct comparisons indicate indistinguishable performance differences between the Nuro-
tron system and other commercially available devices. The present 26-electrode cochlear implant has
already helped to lower the price of cochlear implantation in China and will likely contribute to increased
cochlear implant access and success in the rest of the world.
This article is part of a Special Issue entitled <Lasker Award>.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).ersity of California, Irvine, CA
824 5907.
i District, Shanghai 200031,
nglu@yahoo.com.cn (F. Chi).
B.V. This is an open access article u1. Introduction
Since the United States Food and Drug Administration (FDA)
approved the ﬁrst cochlear implant in 1984, more than 300,000
hearing-impaired people worldwide have used electric stimulation
of the auditory nerve to derive beneﬁts from restoring speech
perception in post-lingually deafened adults to developing lan-
guage in pre-lingually deafened children Clark, 2015, Hochmair,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2015. Cochlear implant technology has evolved from a single-
electrode analog device to multi-electrode devices with inter-
leaved stimulation and in vivo neural recording. Three major
companies, Cochlear Corporation in Australia, Med El in Austria and
Advanced Bionics LLC in the United States, control essentially the
entire market, with Cochlear Corporation being the dominating
player. Despite clearly documented beneﬁts, technological ad-
vances and commercial success, the cochlear implant is still limited
to about 10% of potential candidates in developed countries and
much less in developing countries (Zeng, 2007). The high cost of the
cochlear implants has not changed in the last 30 years despite the
increased volume and is still a major factor limiting market access.
Developing a low-cost, high-performance cochlear implant system
has long been recognized as an effective, perhaps the onlymeans to
increase competition and hopefully market access, particularly in
developing countries (An et al., 2007; Wilson et al., 1998; Zeng,
1995).
The present article describes the conceptualization and process
in developing and evaluating the Nurotron 26-electrode cochlear
implant system, which started with a technology transfer from the
University of California in 2006, received CFDA market approval in
2011 and CE Mark in 2012. As of July 2014, the Nurotron device has
been implanted in 1500 deaf subjects in China, 2 in Columbia and
2 in India. First, the philosophy is presented on the design and
development of the overall system speciﬁcation. Second, speciﬁc
design and veriﬁcation of the system components are laid out
from the external sound processor and radio frequency trans-
mission to the internal receiver, stimulator and intracochlear
electrode array. Third, systematic evaluation results are presented
from objective measures to subjective functional assessments in
60 human subjects who participated in the initial CFDA clinical
trial. Finally, relevant research and socio-economical impact are
discussed.
2. System speciﬁcations
Cochlear implant technologies have converged in the last 30
years e from single-electrode analog stimulation to multi-
electrode interleaved stimulation (e.g., Wilson et al., 2008; Zeng
et al., 2008). Fig. 1 presents the functional block diagram of a
contemporary cochlear implant system, consisting of an external
unit, a transcutaneous radio-frequency (RF) transmission unit, an
internal unit, and a ﬁtting unit that is not worn by the user butFig. 1. A functional block diagram of the Nuused only by clinicians to adjust connection and stimulation pa-
rameters for optimal performance. The external unit is often
called a speech or sound processor and contains a digital signal
processor (DSP) to control signal ﬂow from environmental
sounds to RF transmission. The internal unit includes a hermet-
ically sealed application-speciﬁc-integrated-circuit (ASIC) that
derives power and decodes information from the RF signal, while
delivering electrical stimulation to the electrodes, measuring
feedback signals from the electrodes and transmitting these
measurements back to the sound processor or the clinical ﬁtting
system.
The Nurotron cochlear implant system was developed based on
the following design philosophy. First, the device should meet
technical speciﬁcations that are critical to safety and performance
of a contemporary cochlear implant. The European standard EN
45502-2-3 (2010) and additional modern practices were followed
to conform to safety considerations; multi-channel, multi-stimu-
lation strategies were employed to meet performance needs. Sec-
ond, the device should have a ﬂexible architecture to meet future
needs such as virtual channels or ﬁne structure encoding that could
improve speech recognition in noise, tonal language understanding
and music appreciation. With this philosophy in mind, the ASIC
contained 4 current sources to provide simultaneous stimulation of
2 or 3 electrodes to potentially produce 47 or more spectral chan-
nels. Third, the device should have the capacity to support other
neural prosthetics applications such as auditory nerve implants,
auditory brainstem implants, retinal implants, or deep brain stim-
ulation. To provide this level of expandability, the design included 2
reference electrodes and 24 active stimulating outputs that could
be conﬁgured as 2  12, 3  8, or 4  6 surface electrodes or
penetrating bundles.
Fig. 2 illustrates the Nurotron cochlear implant system. Panel A
shows the behind-the-ear sound processor that contains dual mi-
crophones, control buttons, display lights, battery case, and an RF
transmission coil. A body-worn sound processor (not shown) is also
available for extended battery life or as preferred by some user
groups. Panel B shows the internal components of the system that
contains a gold RF receiving coil, a removablemagnet (with “X” sign
in the middle of the coil to designate polarity), a titanium case, a
plate platinum reference electrode (beside the logo in the case), a
ring platinum reference electrode (at the exit of the electrode
array), and a straight 24-contact electrode array. The following
section describes speciﬁc design and veriﬁcation for the Nurotron
cochlear implant system.rotron 26-electrode cochlear implant.
Fig. 3. The spectrogram (upper panel) and its corresponding electrodogram of the
Nurotron device (lower panel) for a Mandarin sentence “今天你去那里？(Where are
you going today?)”.
Fig. 2. The Nurotron cochlear implant system: The sound processor (A) and the in-
ternal unit containing the receiver, stimulator and electrode array (B).
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3.1. Sound processing
Advanced sound processing is critical to cochlear implant per-
formance. First, sound pre-processing is needed to ensure audi-
bility and clarity of speech sounds. The Nurotron standard pre-
processing includes sensitivity control, automatic gain control,
single microphone noise reduction, and mixed input selection.
Second, sound processing needs to convert analog sound into
electrical pulses. The Nurotron DSP employs 3 processing strate-
gies, including continuous-interleaved-sampling (CIS), advanced
peak selection (APS) and virtual channel (Symphony) strategies.
The CIS strategy employs a ﬁxed number of analysis and stimula-
tion channels, with the actual number being determined by the
number of a subject's usable electrodes up to 24. The APS strategy is
similar to an “n-of-m” strategy, with the maximum number of
analysis channels being 24 while the number of stimulation
channels being typically 6 to 8, dependent on the energy distri-
bution of the input sound and the number of available electrodes.
The APS strategy increases stimulation rate for improved repre-
sentation of temporal ﬁne structure. The Symphony strategy
combines virtual channel and peak selection strategies to addi-
tionally improve the spectral ﬁne structure, in which simultaneous
stimulation of two electrodes is used to generate intermediate
pitch percepts between two these two electrodes.
Fig. 3 shows the spectrum (upper panel) and electrodogram
(lower panel) of a Mandarin sentence of “今天你去那里？(Where
are you going today?)”. In this example, the electrodogram shown
is the output generated by the APS strategy, which divides a
continuous frequency band between 100 and 8000 Hz into 128
linearly-spaced frequency bands. The 128 frequency bands are then
combined into 24 analysis bands based on the Greenwood map
spacing, of which 8 channels with peak energy are selected to
deliver electrical stimulation to the appropriate electrode sites. The
APS was the default strategy used to produce performance data
reported in the user performance result section of this study.
3.2. Radio frequency transmission
The RF unit serves 4 functions, including (1) providing power to
the implant circuit with reasonable transmission efﬁciency, (2)
transmitting data to the implant circuit with high reliability, (3)
synchronizing between the external processor and the implant
circuit while providing timing for the latter, and (4) transmittingfeedback signals to monitor the implant circuit power and status
and to measure electrode impedance and neural responses to
electric stimulation. To accomplish these functions, the Nurotron
external processor employs Pulse Width Modulation (PWM) to
encode digital signals and Amplitude Shift Keying (ASK), a method
of amplitude modulation, to balance transmission efﬁciency and
reliability. A 16-MHz sinusoid is chosen as the carrier frequency. A
Class-E ampliﬁer is employed to achieve high efﬁciency by main-
taining the loaded RF circuit in a quasi-resonant status.
Fig. 4A shows the use of pulse width modulation to encode “0s”
and “1s”, in which bit “0” is coded by 5 RF cycles whereas bit “1” by
10 RF cycles. Fig. 4B shows the actually received 16-MHz RF
waveform (yellow traces) in the implant circuit. Due to the Class-E
ampliﬁer's resonance status, rising ramps and post-modulation
ringing are apparent in the received waveform. In addition, envi-
ronmental interferences, variations in scalp thickness, and relative
movement between the external and internal coils all distort the
received RF signal. Therefore, a robust decoder is needed to reliably
retrieve the digital information. Hysteresis trigger levels are
employed so that signal patterns with 3e7 RF cycles are all decoded
as bit “0”, whereas that with 8e12 cycles as bit “1”. Fig. 4B shows
the recovered envelope of the PWM-coded “0” and “1” (green
traces). This PWM-coded bit signal also provides a 1-MHz clock for
the implant circuit. For back telemetry, a load modulation method,
as commonly used in RFID, uses the same pair of coils to transmit
the implant related data to the external processor. The implant
related data include internal status of the ASIC, compliance voltage,
stimulation waveform, impedance and neural responses.3.3. Receiver and stimulator
The implant circuit receives RF signals to derive power, then to
decode data and command frames to produce electric stimulation.
Common techniques such as parity check, cyclic redundancy check,
data boundary check, and handshaking protocols are used to vali-
date data transmission integrity. Fig. 5A shows the layout of the
Nurotron ASIC receiver and stimulator. The die size is
3594  2499 mm2. The core is a hybrid CMOS chip with mixed
digital and analog circuit. The chip contains 4 current sources,
ensuring reliability and enabling both interleaved and simulta-
neous stimulation, including two-intracochlear-electrode
Fig. 4. The Nurotron RF encoding scheme: Panel A shows the use of pulse width
modulation to encode “0s” and “1s” (Panel A) and Panel B shows the actually received
16-MHz RF waveform (yellow traces) and the recovered “0” and “1” temporal enve-
lopes (green traces).
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well as tripolar stimulation involving three intracochlear
electrodes.
Fig. 5B shows two biphasic pulse trains interleaved between two
channels. Fig. 5C shows detailed waveform of a cathodic-leading
biphasic pulse, with 25-ms phase duration and 2-ms inter-phase
gap. Fig. 5D shows current units (x coordinates) and their corre-
sponding current levels (y coordinates) in term of predicted values
(line) and measured values (circles; from 14 current sources in 7
chips or 2 arbitrarily selected sources per chip). To take advantage
of perceptual electric amplitude coding (Zeng et al., 1994), 4
different current resolutions (2, 4, 8, and 16 mA) are used to encode
the actual current (I ¼ 0e1904 mA) into 256 clinically used Current
Units (CU) that are roughly perceptually equal.
IðmAÞ ¼
8><
>:
2CU
4ðCU  64Þ þ 128
8ðCU  128Þ þ 384
16ðCU  192Þ þ 896
if
0  CU <64
64  CU <128
128  CU <192
192  CU <255
(1)
The accuracy of the current sources is estimated to be 8.0 ± 2.6%
as the percent difference between the speciﬁed and measured
current levels. The tolerance of the current sources is estimated to
be 3.0 ± 1.3% as the ratio between the standard deviation and the
mean of the measured 14 current sources. These two veriﬁcation
measures suggest that no individual calibration be needed in the
amplitude-ﬁtting program.Several measures have been implemented in the ASIC to ensure
safe electric stimulation. First, biphasic pulse stimulation should
be charge balanced, resulting in less than 100 nA DC bias current
(EN 45502-2-3: 2010). Fig. 5E shows accumulated DC current level
as a function of biphasic pulse current level. Without an active
discharge circuit in the ASIC, the DC level exceeds the 100-nA safe
limit at 800-mA current level and above. With the discharge circuit,
the DC level was at 33 nA or less over the entire pulse current
level. Second, to further balance residual charge that may be
applied to tissues, a capacitor is serially connected to each of the
electrodes. Third, to avoid overstimulation causing tissue damage,
maximal charge of any phase is hardware limited to 250 nC
(Shannon, 1992). Fig. 5F shows overstimulation protection model
(dashed line) and actually measured maximal charges under
different pulse duration and current level combinations (circles).
Under no circumstance, does the implemented maximal charge
exceed 250 nC.
Implemented on the ASIC chip is a programmable gain ampliﬁer
with a maximal gain of 60 dB and a 12-bit analog-to-digital
convertor for back telemetry. As a result, a 10 mV change can be
detected to support recording of neural responses. Electrode
impedance can be measured with 5% tolerance.
3.4. Electrodes (24 þ 2)
A ﬁnal step towards cochlear implant hearing is electric stim-
ulation of the auditory nerve via a 24-intracochlear-electrode array.
Optimally, this electrode-nerve interface should support high levels
of subject performance, minimize the occurrence and severity of
insertion related trauma, and demonstrate excellent long-term
reliability. The physical characteristics of individual cochlear
implant electrode designs have been clearly associated with the
incidence of intracochlear trauma in studies using human cadaver
temporal bones (Rebscher et al., 2008, 1999; Wardrop et al., 2005a;
Wardrop et al., 2005b) and intracochlear trauma has been corre-
lated with signiﬁcant reductions in subject performance
(Aschendorff et al., 2007; Carlson et al., 2011; Finley et al., 2008).
Based on these studies, it is important for the electrode array to be
sufﬁciently small to ﬁt within the wide variety of scala tympani
dimensions. Additionally, the Nurotron electrode array in-
corporates greater stiffness in the vertical plane of the cochlear
spiral than in the horizontal plane which has been shown to be one
successful strategy to minimize the occurrence of vertical deviation
into the scala media or scala vestibuli.
The Nurotron electrode consists of an injection molded silicone
elastomer carrier supporting 24 intracochlear stimulating contacts
and 2 extracochlear reference electrodes. Fig. 6A shows the ﬂexible
tip and 7most distal electrode contacts. The active contacts have an
exposed surface area of 0.2 mm2 and are located at intervals of
0.8 mm on the inner surface of the electrode to be oriented toward
target neurons in the modiolus. The maximum charge density is
1.25 mC/mm2 (¼250 nC/0.2 mm2). Taking into account that a plat-
inum contact with smooth surface has a roughness factor of 1.4, the
actual maximum charge density is more likely 0.9 mC/mm2, well
below the safety limit of electric stimulation (Brummer et al., 1983).
Fig. 6B shows the contact sites and leads from the opposite side of
the array. The tapered ends of each contact are securely embedded
in the silicone carrier. Fig. 6C illustrates the coiled wire lead cable.
The total recommended insertion length of the array is 22.0 mm,
corresponding to an insertion depth of roughly 400 by a straight
electrode array in an average-sized cochlea (e.g., Franke-Trieger
et al., 2014). These 24 active intracochlear contacts and the rela-
tively deep insertion support high levels of subject performance as
reported below. To accommodate the size of the human scala
tympani, the Nurotron electrode array is 0.70(H)  0.56 mm(W) at
Fig. 5. The Nurotron receiver and stimulator. Panel A shows the ASIC die conﬁguration. Panel B shows two interleaved biphasic pulse trains. Panel C shows detailed waveform of a
cathodic-leading biphasic pulse, with 25-ms phase duration and 2-ms inter-phase gap. Panel D shows current units as a function of current levels in term of predicted values (line)
and measured values (circles; from 14 current sources in 7 chips). Panel E shows accumulated DC current level as a function of biphasic pulse current level, with (solid line) and
without (dashed line) an active discharge circuit. Panel F shows overstimulation protection implementation suggested by the model (dashed line) and measured by different pulse
duration and current level combinations (circles).
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within all documented human scala tympani cross sections
(Rebscher et al., 2008). Fig. 6D shows that the Nurotron electrode
array ﬁts within the outlines of a set of randomly selected human
scala tympani cross sections in the base (90) and near the elec-
trode tip at 360.
As described above, the Nurotron electrode is mechanically
stiffened in the vertical plane as a strategy to reduce the incidence
of damage resulting from vertical deviation of the electrode tip.
Physical measurements of the array indicate a ratio of 2.5e3.0
between vertical stiffness and horizontal stiffness, similar to that
reported for other electrode designs which have demonstrated
signiﬁcant reduction in insertion associated trauma (Rebscher
et al., 2008; Wardrop et al., 2005a). Preliminary temporal bonestudies, and post-surgical clinical radiography, have conﬁrmed
that the Nurotron array can be reliably inserted to the 22 mm
recommended insertion depth without signiﬁcant trauma. To
validate reliability, connection of the electrode array to the
implanted stimulator, repetitive ﬂex testing of the spiral coiled
interconnect cable and the intracochlear electrode itself have been
conducted to meet the European standard (EN 45502-2-3: 2010).
A ﬁnal design consideration in reducing traumatic insertions,
which have been associated with poor cochleostomy placement,
incomplete visualization of the basal scala tympani, angular
misdirection of the electrode tip or a combination of these three
factors, is to facilitate a simpliﬁed insertion technique. The Nuro-
tron electrode is shaped as a straight array with moderate overall
Fig. 6. The Nurotron 24 channel intracochlear electrode array. Fig. 6A shows the ﬂexible tip of the electrode array and 7 distal sites of the 24 stimulating contacts, being equally
distributed with a pitch of 0.8 mm along the 22.0 mm array and with each contact having a surface area of 0.2 mm2. Fig. 6B shows the contact sites and leads from the opposite side
of the array. The tapered ends of each contact are securely embedded in the silicone carrier. The organized vertical arrangement of the wire leads is also visible in this image. Fig. 6C
illustrates the coiled wire lead cable. A critical factor in minimizing insertion related trauma is the ﬁt of the electrode array within the conﬁned cavity of the scala tympani. To ensure
that the Nurotron array would safely ﬁt in the range of cochlear dimensions observed across the subject population, the design was modeled in a series of cochlear cross section
outlines (Fig. 6D) measured at 90 (35 bones) and 360 (31 bones) intervals (Rebscher et al., 2008). These measurements indicate that the Nurotron array occupies approximately
25e30% of the cross sectional area of the scala tympani at each location evaluated and ﬁt within all scala tympani proﬁles previously documented.
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insertion tool or stylet.3.5. Packaging and MRI compatibility
Twenty-ﬁve platinum feedthroughs are placed in the bottom of
the titanium case and connected to an internal PCB on one end, the
24-intracochlear electrodes and the ring reference electrode on the
other. The titanium case has a volume of 12.8 ml
(36.4  33.0  6.9 mm3), but with only 3.9-mm spacing being ex-
pected between the skin and the mastoid surface because a 3-mm
deep recess is routinely drilled in the bone to securely house the
implant and minimize its movement. Three additional platinum
feedthroughs on the sidewall of the case are connected to the two
ends of the RF coil and the plate reference electrode, respectively.
Silicone coating and molding form and shape the ﬁnal package of
the implant. Biocompatibility tests were performed and approved
by the CFDA testing facility before human clinical trial. Hermetic
seal, measured by the helium-gas leakage rate, is less than
1  109 atm cm3/second (EN 45502-2-3: 2010).
MRI compatibility at 1.5T has been veriﬁed for the Nurotron
cochlear implant. In the heat generation test, the implant without
the magnet, was placed into a 15-ml container ﬁlled with 9 g/l
saline. An identical container without the implant served as con-
trol. 15-min MRI scan produced no signiﬁcant difference in tem-
perature between the two containers, with a temperature rise in
the implant case or at the electrode tip being less than 2 C. In
addition, the MRI scan produced a charge of 0.06 nC, less than the
10-nC safe limit (EN 45502-2-3: 2010). Finally, the 15-min MRI
operation produced no noticeable change in function and perfor-
mance of the implant device.4. System evaluation
4.1. Methods
4.1.1. Subjects
Sixty subjects participated in the Nurotron cochlear implant
clinical trial from December 2009 to October 2010. They were 34
males and 26 females, with a mean age of 26 ± 12 years old
(range ¼ 6e59 years old). The cochlear implantation candidacy
criteria followed the standard issued by Chinese Ministry of Health
(Chinese Ministry of Health, 2007). The mean duration of deafness,
deﬁned as bilateral pure-tone-average thresholds (0.5, 1, 2 and
4 kHz) greater than 85 dB HL, was 7 ± 5 years (range ¼ 0.3e15
years). The actual pre-surgical pure-tone-average thresholds were
107 ± 11 dB HL. The etiologies included ototoxicity (n ¼ 31),
enlarged vestibular aqueduct syndrome (7), sudden onset hearing
loss (5), meningitis (2), noise exposure (2), and unknown causes
(13). These subjects were from 18 provinces in China. Each subject
and his or her family consented to participate in the clinical trial,
with a protocol that was approved by the local Human Research
Ethics Committee of each of the ﬁve participating hospitals,
including Shanghai Fudan University (n ¼ 23), Beijing PLA General
Hospital (15), Beijing Tongren Hospital (10), Zhejiang University (7),
and Chongqing Medical University (5). At the end of the ﬁrst year, 3
subjects dropped out the clinical trial, with 2 being unable to be
tested at the 4- and 6-month periods and 1 being disqualiﬁed for
having a pre-surgical pure-tone-average threshold that was 5 dB
lower than the 85 dB HL inclusion criterion. The one-year clinical
trial data were submitted to Chinese FDA and received its approval
on August 19, 2011. However, follow-up continued with data being
collected in 48 subjects until the end of the third year; the addi-
tional 9 subjects dropped out due to their inability or unwillingness
to be tested at the speciﬁed times.
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Twelve neurotologists, who all had prior experience in cochlear
implant surgery, used a soft surgical approach to perform mas-
toidectomy and cochleostomy in the 60 participants. An incision
was made in the skin behind the ear. A 0.44-mL, or 440-mm3, bed
was created to securely house the receiver and stimulator case
before entry into the middle ear. The facial recess was opened, and
the bone anterior to the facial nerve was removed to provide wide
exposure of the round window niche. A small cochleostomy hole
was made in a position inferior and anterior to the round window
niche with a 1.0- or 0.5-mm diamond burr. The cochleostomy hole
was drilled until the blue lining of the endosteum became visible.
A small amount of sodium hyaluronatewas gently injected into the
scala tympani to prevent ﬂuid leak and entry of foreign bodies
such as bone dust. Suctionwas prohibited at this stage to avoid loss
of perilymphatic ﬂuid. The electrode array was then inserted into
the scala tympani. The cochleostomy was then sealed with a small
amount of connective tissue. After implantation, electrode
impedance and electrically evoked stapedius reﬂex were typically
measured to verify device integrity and functionality. The total
time of implantation ranged from 30 to 120 min, dependent on
surgeon's experience and subject's condition. Although all 12
surgeons encountered no signiﬁcant difﬁculty in inserting the
electrode array, 4 recommended an insertion tool be used in the
future.
To estimate the electrode position and insertion depth (Verbist
et al., 2010; Xu et al., 2000), 48 subjects had X-ray of the cochlear
implant after their surgeries. The average insertion depth was 449,
with a standard deviation of 79, which was slightly deeper than
the designed insertion depth of 400. Of these 48 subjects, 37 had
all of the 24 electrodes properly placed in the cochlea (e.g, Fig. 7A),
whereas 11 had a buckled or mislocated electrode array, especially
near the round window (e.g., Fig. 7B), indicating the need for
further evaluation of the electrode design and surgical procedure.
The effect of a buckled or mislocated electrode array will be
addressed in the discussion section.Fig. 7. In vivo high-resolution X-ray pictures of the Nurotron cochlear implant device. A. A
array. The proﬁle of the receiving coil, magnet, case, and feedthroughs are seen on the left sid
electrode contacts are seen in the lower part of the picture. B. A user with a smooth electrod
cable (upper arrow) and knotted electrode contacts near round window (lower arrow). The
contacts were due to forceful insertion. This subject had 6 unusable electrode contacts and4.1.3. Stimuli
Two open-set tests of Mandarin sentence recognitionwere used
for evaluation of the Nurotron cochlear implant performance. The
House sentence recognition test included 10 lists of 10
phonetically-balanced sentences with each containing 7 key words
(Fu et al., 2011). The 301 sentence recognition test included 12 lists
of 11 sentences with each containing 6e8 key words, for a total of
57 words (Xi et al., 2012). Percentage of correctly identiﬁed words
was used as the open-set sentence recognition score. Because no
statistical differencewas found between the two tests, the averaged
scores were used in data analysis and reported here. In addition, 3
closed-set tests of Mandarin consonants, vowels, and tones were
used, inwhich each test had four alternatives and the subject had to
choose one of them (http://www.tigerspeech.com).
The default speech processing was the multi-peak APS strategy.
The default stimulation was monopolar mode using both reference
electrodes (MP1 þ 2). Electrode impedance was estimated by a
single biphasic pulse with a 40-ms pulse duration. The threshold
and comfort loudness levels were estimated by a 500-ms, 1000-Hz
biphasic pulse train. The pulse duration was either 25 or 50 ms/
phase. Speech stimuli were presented to the subject at 65 dB SPL in
a sound ﬁeld condition.
4.1.4. Procedures
As part of the informed consent, all subjects agreed to partici-
pate in a pre-surgical test and 5 post-surgical tests at 1, 2, 4, 6 and
12 months. The additional tests at 24 and 36 months were volun-
tary. During each test, the subject went through a full battery of
audiometric tests including air-conducted pure-tone thresholds,
electric impedance, threshold (T) and comfortable (C) levels for
each electrode, and both closed-set phoneme and open-set sen-
tence recognition. In addition, the subject went through a full
physical examination, including vital signs, blood and urine tests,
electrocardiogram, thoracic roentgenoscopy, visual examination for
surgical complications such as swelling, infection, facial paralysis,
and hematoma. All tests were performed independently byuser with a proper placement of the receiver, stimulator and intra-cochlear electrode
e of the picture, while the electrode cable (“z” shaped in the picture) and the coiled 24-
e cable and electrode contacts near round window. C. A user with a buckled electrode
buckled cable was likely due to improper pinch by surgical tweezers while the knotted
a 73% correct sentence recognition score.
F.-G. Zeng et al. / Hearing Research 322 (2015) 188e199 195audiologists and physicians, under supervision of a certiﬁed con-
tract research organization.
4.2. Results I: objective measures
During the ﬁrst year clinical trial period, 6 adverse events were
noted, including 2 possibly related to surgery (swelling in the eyelid
and swelling in the surgery area) and 4 unrelated to the surgery or
the device (2 mild fatty liver cases, 1 acute nephritis, and 1 upper
respiratory tract infection). The physicians determined that none of
these adverse events was directly related to the Nurotron device.
Fig. 8 shows impedance as a function of electrode position at the
device switch-on time (upper panel) and as a function of the
implant usage time (lower panel). At the time of switch on, elec-
trode impedance was 13 ± 3 kU, which was not signiﬁcantly
different as a function of electrode position [F(23,771) ¼ 0.7,
p > 0.05; univariate ANOVA]. However, the impedance averaged
over the entire electrode array changed signiﬁcantly with implant
use [F(23,242) ¼ 20.2, p < 0.01]. The average impedance decreased
signiﬁcantly by 6 kU from switch on to 1 month, stayed unchanged
over the 12-month period (p > 0.05), and increased signiﬁcantly by
2 kU at the 24-month evalation (p < 0.05; Post Hoc tests with
Bonferroni correction for these and other comparisons in the
remainder of the results section).Fig. 8. Average electrode impedance as a function of electrode position at the device
switch-on time (upper panel) and as a function of device usage time (lower panel). The
“*” symbol indicates signiﬁcance at p < 0.05 level.4.3. Results II: psychophysical measures
The upper panel of Fig. 9 shows threshold (T) and comfortable
(C) levels as a function of electrode position at the device switch-on
time. Both T and C levels showed a signiﬁcantly increasing trend as
a function of electrode position at the time of switch on
[F(23,711) ¼ 3.1, p < 0.01, F(23,717) ¼ 3.3, p < 0.01, for T and C levels
respectively]. Compared with the most apical electrode (#1), post-
hoc analysis revealed signiﬁcant higher T levels for electrode 23
and 24 and higher C levels for electrodes 22, 23 and 24 (p < 0.05).
Note that these different T and C levels cannot be attributed to
electrode impedance, which was not signiﬁcantly different be-
tween electrodes (Fig. 8).
The lower panel of Fig. 9 shows the averaged T and C levels over
the entire electrode array as a function of the implant usage time.
The T level had been stable over the 36 month period
[F(7,226) ¼ 0.4, p > 0.05]. Interestingly, the C level increased over
time [F(7,226) ¼ 2.3, p < 0.05], with the C level at 36 months being
signiﬁcantly greater than that at the time of switch on [p < 0.05].
This increased C level possibly reﬂects the increased tolerance to
electric stimulation of the auditory nerve (Zeng, 2013).4.4. Results III: functional measures
Fig. 10 shows that sentence recognition varied greatly among
subjects (dotted lines) but improved signiﬁcantly as a function of
implant usage over the 36-month period [F(7,426) ¼ 132, p < 0.01].Fig. 9. Average T and C levels as a function of electrode position at the device switch-
on time (upper panel) and as a function of device usage time (lower panel). The “*”
symbol indicates signiﬁcance at p < 0.05 level.
Fig. 10. Individual (dotted lines) and average (circles connected by a solid line) sen-
tence recognition scores as a function of device usage time. The “*” within the circle
represents a signiﬁcant difference over the previous test time.
Fig. 11. Individual (dotted lines) and average (circles connected by a solid line)
recognition scores as a function of device usage time for consonants (upper panel),
vowels (middle panel) and tones (lower panel). The “*” within the circle represents a
signiﬁcant difference over the previous test time.
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average score of 0.03% correct before cochlear implantation to 27%,
41% and 68% correct at the 1-, 2- and 4-month test time, respec-
tively (p < 0.05). The cochlear implant performance reached a
plateau after 6 months, with the highest recognition of 89% at the
36-month evaluation.
Using the same format, Fig.11 shows percent correct recognition
as functions of time for consonants (upper panel), vowels (middle
panel) or tones (lower panel). Overall, phoneme recognition was
similar to sentence recognition (Fig. 11), varying greatly among
subjects (dotted lines) and improved signiﬁcantly as a function of
time [F(7,426) > 45, p < 0.01]. Different from sentence recognition,
consonant and vowel recognition reached a plateau after only 4-
month usage. Similar to sentence recognition, tone recognition
reached a plateau after 6-month usage, reinforcing the importance
of tone recognition inMandarin speech recognition (Fu et al., 1998).
5. Discussion
In this section, the Nurotron device is compared against other
devices from both technical and performance perspectives. Several
relevant studies using the Nurotron device are also summarized
and discussed. Finally, the socio-economical impact of the present
developmental effort is discussed.
5.1. Technical comparison
Table 1 compares key technical parameters of the Nurotron
cochlear implant against presently available devices by the three
major cochlear implant manufacturers. Although the Nurotron
device was conceived in 2005 and developed into a product in
2008, it is still technically comparable by today's standards. A
reason for this comparability is that cochlear implant advances in
the last decade have been mostly in pre-processing and cosmetics,
with little changes in speech processing strategies, RF transmission
and receiver and electrode arrays.
In terms of the external unit, all devices, including the Nurotron
device, have similar technical parameters from a relatively wide
input dynamic range (75e80 dB) and a frequency range (~8000 Hz)
to the default processing strategy (CIS-like) and the number of
maps in the processor (4e5). Note that the Nurotron processor has
the shortest battery life, reﬂecting a lack of design consideration for
optimal power consumption. Also note that the Nurotron processorlacks wireless connectivity, reﬂecting design priority consider-
ations in 2005. Both power consumption and connectivity prob-
lems are being addressed by Nurotron, but are beyond the scope of
discussion for the present study.
Although there is no manufacturer-speciﬁc systematic report on
in vivo electrode array status, buckled or mislocated electrode ar-
rays are believed to be present in all devices, e.g., as high as 40%
electrodes mislocated in scala vestibuli in some cases (Holden et al.,
2013; Kong et al., 2012; Skinner et al., 2007; Wardrop et al., 2005a,
2005b). It is unclear whether the incidence of the presently
Table 1
System speciﬁcations of the Nurotron 26-electrode cochlear implant compared with other three major cochlear implant systems. Data Sources: Cochlear N6 (User Guide and
Technical Speciﬁcations fromwww.cochlear.com); Clarion HiRes 90 K (www.bionicear.com); Med El Maestro implant system (Hochmair et al., 2006). Additional information
from. http://cochlearimplantonline.com
System units Parameters Nurotron Venus Nucleus N6 AB HiRes 90 K Med-El MAESTRO
External unit Name and key features Venus: Omni or directional
mics
IDR (75 dB)
Freq range: 100e8000 Hz
Li-Ion or 3 Zinc Air batteries
(8e24 h)
N6: Omni or directional mics
IDR (75 dB)
Freq range: 100e8000 Hz
2 Zinc Air or recharge.
batteries (18e60 h)
Harmony: T-mic
Dual-loop AGC
IDR (20e80 dB)
Freq range: 150e8000 Hz
Li-Ion batteries (12e56 h)
OPUS2: Omni mic
Dual-loop AGC
IDR (75 dB)
Freq range: 70e8500 Hz
3 zinc-air batteries
(12e90 h)
Processing strategies CIS
APS
Virtual channel
SPEAK
ACE
Hi-ACE
CIS
MPS
HiRes Fidelity 120
CISþ
HD CIS
FSP
Number of maps 4 4 5 4
Connectivity Direct Audio Input Direct Audio Input
Wireless
Direct Audio Input
Wireless
Direct Audio Input
Wireless
RF unit RF carrier 16 MHz 5 MHz 49 MHz 12 MHz
Data rate 0.9 MB/Sec 0.5 MB/Sec 1 MB/Sec 0.6 MB/Sec
Internal unit Total stimulation rate 40 KHz 32 KHz 83 KHz 51 KHz
Number of current
sources
4 1 16 24
Max current 1.9 mA 1.75 mA 1.9 mA 1.2 mA
Number of
intracochlear electrodes
24 22 16 12
Number of reference
electrodes
2 2 2 2
Simultaneous stimulation Yes No Yes Yes
Fitting unit Impedance measure Yes Yes Yes Yes
Chinese Interface Yes No No No
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devices, and whether these cases are due to the inexperience of
some of the surgeons themselves, or their unfamiliarity with a new
device. Nevertheless, post-surgical analysis showed that the
average number of unusable electrodes is 4 (range ¼ 0e13) in
subjects with buckled or mislocated arrays, compared with 1
(range ¼ 0e10) in other subjects. The corresponding average sen-
tence recognition score was 70 ± 18%, compared with 79 ± 19%
correct. Neither the difference in the number of unusable elec-
trodes nor that in the sentence recognition score reaches a statis-
tically signiﬁcant level (p > 0.05), possibly due to the relatively
small sample size. To highlight the complicated subject and device
interactions, the subject with the most unusable electrodes (¼13)
actually had one of the highest sentence recognition score (¼92%).
Except for having the most intracochlear electrodes, the key
technical parameters for the Nurotron RF and internal units are
roughly in the middle of other currently available devices. For
example, the 16-MHz RF carrier is lower than the 49-MHz AB de-
vice but higher than the 5-MHz Nucleus and 12-MHz Med El de-
vices; the 40-KHz total stimulation rate is higher than the 32-KHz
Nucleus device but lower than the 83-KHz AB and 51-KHz Med El
devices; the 4 current sources are more than the 1-source Nucleus
device but less than the 16-source AB and 24-source Med El de-
vices. As can been from the remainder of the discussion, these
differences in technical parameters reﬂect philosophical differ-
ences in design but have not produced any measurable differences
in performance.
5.2. Performance comparison
The Nurotron device has produced similar performance to other
devices in terms of basic objective and subjective measures. The
present electrode impedance (Fig. 8) and stimulation level (Fig. 9)
effects are generally consistent with a large body of existing studies
from other cochlear implant devices (e.g., Henkin et al., 2003, 2005,
2006; Hughes et al., 2001; Mosca et al., 2014; van Wermeskerken
et al., 2006). In addition to a larger sample size and longerobservation time (3 years vs. 1e2 years), the present study extends
previous studies in the following ways. First, the absence of elec-
trode position effect on impedance (Fig. 8A) suggests that electrode
impedance reﬂects mostly the electrode physical properties such as
area and the dynamic interplay between electrode and nearby
tissues in electric stimulation (e.g., Clark et al., 1995), whereas the
presence of electrode position effect on loudness levels (Fig. 9A)
suggests that behavioral measures reﬂect more the overall electric
ﬁeld property, the survival nerve extent and distribution, and
central factors (e.g., Tang et al., 2011). The non-monotonic function
of impedance versus time (Fig. 8B) and the monotonic function of
loudness versus time (Fig. 9B) lend further support for the idea that
increased loudness tolerance with prolonged electric stimulation
reﬂects more a decreased central gain in the brain rather than
changes in electric properties in the cochlea (Zeng, 2013). The
greater amount of this loudness change in children than in adults
(e.g., Henkin et al., 2003, 2005, 2006; Hughes et al., 2001) is
consistent with greater plasticity in the developing brain.
The Nurotron device has produced functionally indistinguish-
able performance from other devices in speech recognition mea-
sures. Fig. 12A shows comparison in sentence recognition between
4 cochlear implants. The Advanced Bionics data were from 51
subjects who had used the HiRes processing strategy for 3 months
after prior 3-month experience with conventional strategies, CIS or
SAS (Koch et al., 2004). The Med El data were 14 subjects who had
used the ﬁne structure processing strategy after an average 1-year
experience with the CIS strategy (Arnoldner et al., 2007). The
Cochlear data were from 55 subjects who participated in the Nu-
cleus Freedom North America clinical trial and had used the
Freedom device for 6 months (Balkany et al., 2007). As a compari-
son, the Nurotron data were from the 6-month performance, which
was signiﬁcantly higher than the 3-month performance but lower
than, although not signiﬁcantly different from, the 1-year perfor-
mance (Fig. 10). Despite the fact that Advanced Bionics and
Cochlear used English sentences, Med El used German sentences
and Nurotron used Mandarin sentences, and additionally these
clinical trials were conducted by different researchers and under
Fig. 12. Sentence recognition between the Nurotron device and the other three devices
using different test materials and protocols (upper panel) and sentence recognition
between the Nurotron and Cochlear devices using the same test materials and pro-
tocols (lower panel).
F.-G. Zeng et al. / Hearing Research 322 (2015) 188e199198different protocols, all 4 devices produced functionally equivalent
performance between 60 and 80% correct for sentence recognition
in quiet.
In a more tightly controlled study, researchers at Beijing 301
Hospital (Li et al., 2014) directly compared performance between
Nucleus and Nurotron devices by recruiting two groups of subjects
whowere matched in age (29 ± 13 vs. 25 ± 9 years old), duration of
deafness (7 ± 5 vs. 7 ± 4 years), gender (9 males and 6 females vs. 10
males and 5 females), and other audiological and etiological factors.
Using the same surgical and evaluation protocols including the
same Mandarin speech test materials, they found no statistically
difference in performance between these two devices. Fig. 12B re-
plots the subjects' sentence recognition data after 2-year usage of
their respective Nucleus and Nurotron devices. The Nucleus users
produced 87 ± 14% correct score while the Nurotron users pro-
duced 83 ± 21% score. The high level of speech performance by the
Nurotron device as well as its ability to improve quality of life has
been independently veriﬁed by other researchers at Beijing Tong-
ren Hospital (Liu et al., 2014), Central South University Xiangya
Hospital (Yu, 2013), and China Rehabilitation Research Center for
Deaf Children (Yu, 2013).5.3. Socio-economical impact
Thanks to pioneers such as William House, Blair Simmons,
Robin Michelson (Eisenberg ref and Merzenich ref in this issue), as
well as the three 2013 Lasker Award winners: Graeme Clark,
Ingeborg Hochmair and Blake Wilson, the cochlear implant has
helped restored partial hearing to more than 300,000 adults andchildren worldwide. Unfortunately, only a fraction of the current
cochlear implant users reside in developing countries, despite the
fact that these countries boast more than 80% of the world popu-
lation. While a lack of competition, a lack of awareness and a lack of
access all contribute to some extent, high price is the prohibitive
factor limiting the widespread use of the cochlear implant (Zeng,
2007).
To our knowledge, the Nurotron cochlear implant represents the
ﬁrst time an implantable, active medical device has ever been
developed and manufactured in a developing country. Although
the commercial operation is still in infancy, the successful devel-
opment of the Nurotron device, as shown here, has not only broken
technical barriers, but also produced a signiﬁcant socio-economical
impact. Thanks to this emerging product and the competition it has
brought about, at present, 3 deaf children in China can beneﬁt from
the cochlear implant for the price that would allow only child to
receive a device several years ago. It is expected that the cochlear
implant will continue to drop in cost while improving performance,
beneﬁtting hearing-impaired people living in both developed and
developing countries.6. Summary
The present article describes the development and evaluation of
a 26-electrode Nurotron cochlear implant that is comprised of an
external sound processor, a radio-frequency transmission link and
an internal receiver and stimulator. The default sound processing
strategy uses multi-peak interleaved stimulation, while the default
mode is monopolar stimulation with an active electrode being one
of the 24 intracochlear electrodes and both extra-cochlear elec-
trodes being the reference. Sixty severe-to-profoundly hearing-
impaired subjects had participated in a 1-year clinical trial with
some of them being continuously followed up for 3 years. Similar to
other commercially available cochlear implants, the Nurotron de-
vice showed a decrease in electrode impedance within the ﬁrst
month implant use, a stable threshold level, and an increased
comfort level over the 3-year period. Mandarin speech recognition
signiﬁcantly improved from the pre-implantation level to 4-month
usage, reaching a plateau high-level performance of about 80%
correct after 6-month usage. Both indirect and direct comparisons
indicated that the Nurotron 26-electrode cochlear implant and
other commercially available devices produced indistinguishable
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